drugset / Trial / NCT04972539

Evaluation of Pharmacokinetics and Safety of AJU-A51 in Healthy Adults

NCT04972539

Phase 1 Completed 48 enrolled AJU Pharm Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

To evaluate the safety and pharmacokinetic characteristics of AJU-A51 in healthy adults

Timeline

Start
2020-08-01
Primary completion
2020-11-30
Completion
2021-03-09

Drugs

EvaluationDrugModalityDoseRoute
Subject AJU-A51 Unknown 5 mg Oral
Subject AJU-A51 Unknown 10 mg Oral
Subject Dapagliflozin Small molecule 10 mg Oral
Subject Linagliptin Small molecule 5 mg Oral